There have been many reports on serologic autoantibodies in inflammatory bowel diseases (IBD),1 consisting of ulcerative colitis (UC) and Crohn's disease (CD), and recently Kuwada et al2 reported a new autoantibody against integrin αvβ6 with high sensitivity and specificity for UC. Concurrently, we had discovered autoantibodies against endothelial protein C receptor (EPCR) in Takayasu arteritis (TAK), which is sometimes complicated by UC.3 Interestingly, this autoantibody was found in most patients with TAK associated with UC, and we found that the positivity rate in patients with UC without TAK was also high, suggesting that anti-EPCR antibody is a candidate autoantibody useful for the diagnosis of UC.4 To clarify the diagnostic usefulness of anti-EPCR antibodies in patients with IBD and their relationship to several disease subphenotypes and their disease activities, we analyzed the serum samples from patients with IBD and non-IBD control subjects in Japan and the United States.

中文翻译：

---

溃疡性结肠炎患者抗内皮蛋白 C 受体的新型诊断性自身抗体。

关于炎症性肠病 (IBD) 血清学自身抗体的报道很多，包括溃疡性结肠炎 (UC) 和克罗恩病 (CD)，最近 Kuwada 等人2 报道了一种针对整合素 αvβ6 的新型自身抗体，对 UC 具有高敏感性和特异性. 同时，我们在大动脉炎 (TAK) 中发现了针对内皮蛋白 C 受体 (EPCR) 的自身抗体，有时并发 UC。3无 TAK 的 UC 患者的检测率也很高，表明抗 EPCR 抗体是可用于诊断 UC 的候选自身抗体。